Cameron’s Law

HR 1414, titled "Cameron’s Law," increases the tax credit for pharmaceutical companies developing orphan drugs (medicines for rare diseases) from 25% to 50% of qualified research expenses. This change directly affects drug manufacturers investing in treatments for conditions affecting fewer than 200,000 people in the U.S. The bill amends the Internal Revenue Code to implement this higher credit rate, effective for taxable years starting after the law’s enactment. It provides a concrete financial incentive to encourage research into rare disease treatments without altering eligibility criteria or adding new requirements.